多项指标对慢性持续期哮喘联合治疗方案调整效果评价_高燕.pdf

336 2009 9285 　Journal of Cardiovascular Pulmonary Diseases, September 2009,Vol.28, No.5 DOI:10.3969 j.issn.1007-5062.2009.05.013 ·· 高 燕　孙 丽　赵海涛 　　〔〕　:(AR)〔 1(FEV )≥20% 1 (PD FEV )〕, (ACT)、(EOS)、E 20 1 (IgE)、FEV (FEV %pred)、(PEF% 1 1 pred), (ICS)+β2 (LABA) 。 :3 、 ICS+LABA , 。 :1. ICS+LABA , 、FEV %pred、 1 PEF%pred 、ACT 、AR(EOS)。 9 、12 、15 18 26.%、 2.8%、58.8%60%。 2.30 , 7 , AR、EOS 2 , 1 6 AR、 EOS 。 :、 (GOAL)。 〔〕　;;; + 〔〕　R562.2 5　　〔〕　A　　〔〕　1007-5062(2009)05-336-0 The evaluation of multiple markers on the treatment effects in chronic persistent asthma with combined drug therapy　GAO Yan, SUN Li, ZHAO Haitao 　Department of Emergency, General Hospital Shenyang Military Command, Shenyang 110016, China [Abstract] 　Objective:To evaluate the effect of airway responsiveness (AR), asthma control test (ACT) scores, blood eosinophil (EOS)count, serum immunoglobulin E(IgE), asthma symptom scores, forced expiratory volume in one second accounting for percentage of predicted volume(FEV %pred)and morning peak expiratory flow 1 accounting for percentage of predicted volume(PEF%pred)on the treatment of chronic persistent asthma with inhaled corticosteroid(ICS)plus long-acting β2 agonist(LABA ).Method:3 cases of asthma patients (mild or moderate) with ICS+LABA were enrolled, and above parameters were used to adjust treatment program.Result:1.AR, ACT scores FEV %pred, PEF%pred, asthma symptom scores and EOS count were significantly improved after ICS 1 combined LABA therapy.The full control rate in 9 months, 12 months, 15 months and 18 mont